Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Takeda Pharmaceutical Company Limited

Takeda Oncology

BioLife Plasma Services

Takeda Canada Inc.

TAKEDA IBDpoint

Innovation Capability Center at Takeda

Dengue Academy

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society.We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities.

msh id	COM:TAKEDA
symbol	4.5K
name	Takeda Pharmaceutical Company Limited
homepage url	https://www.takeda.com
country	JP
sector	Healthcare
industry	Drug Manufacturers - Specialty & Generic
market	STOCKS
employee count	49.28K
crunchbase url	-
linkedin url	-
founders	-

market cap	44.21B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	80.76
growth score 28	50.84
growth score 90	45.83
growth score 365	81.37

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.14
growth cost of revenue	0.12
growth depreciation and amortization	0.14
growth ebitda	0.15
growth ebitda ratio	0.02
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	0.13
growth gross profit ratio	0

COM:TAKEDA

Takeda Pharmaceutical Company Limited

Last Close

4,182.00

21/11 06:45

Market Cap

6.77T

Beta: -

Volume Today

3.98M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	19.95B
cost of revenue	19.95B
depreciation and amortization	3.8B
ebitda	6.76B
ebitda ratio	0.29
eps	0.94
eps diluted	0.94
operating expenses	12.85B
operating income	2.96B
operating income ratio	0.13

accounts receivables	482.31M
capital expenditure	-4.07B
cash at beginning of period	5.45B
cash at end of period	3.43B
inventory	5.48B
working capital ttm	146.66B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-